TY - CHAP M1 - Book, Section TI - Chapter 518. Pulmonary Alveolar Proteinosis A1 - Trapnell, Bruce C. A1 - Young, Lisa R. A2 - Rudolph, Colin D. A2 - Rudolph, Abraham M. A2 - Lister, George E. A2 - First, Lewis R. A2 - Gershon, Anne A. PY - 2011 T2 - Rudolph's Pediatrics, 22e AB - Pulmonary alveolar proteinosis (PAP) is a syndrome characterized by the accumulation of surfactant lipids and proteins within the pulmonary alveoli, resulting in impaired gas exchange and respiratory insufficiency.1 Our understanding of PAP has advanced significantly over the past several decades due to a series of contributions from basic, clinical, and translational research.2,3 These studies have revealed a critical role for pulmonary granulocyte/macrophage-colony stimulating factor (GM-CSF) in the terminal differentiation of alveolar macrophages and in alveolar macrophage-mediated surfactant catabolism, pulmonary surfactant homeostasis, and lung host defense.4-6 PAP comprises part of a larger group of disorders associated with disruption of surfactant homeostasis and includes disorders of surfactant production (hereafter referred to as pulmonary surfactant metabolic dysfunction disorders) and disorders of surfactant clearance (hereafter referred to as PAP; Table 518-1). The distinct epidemiological, pathogenic, clinical, and prognostic features of these two disease categories indicate they are usually considered separately rather than as a continuum of a single disease process. PAP can be further divided into primary and secondary PAP, which, respectively, are associated with either loss of GM-CSF signaling or the presence of an underlying disorder that reduces alveolar macrophage numbers or functions. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/04/20 UR - accesspediatrics.mhmedical.com/content.aspx?aid=7052114 ER -